{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T02:54:20Z","timestamp":1781319260800,"version":"3.54.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T00:00:00Z","timestamp":1565308800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T00:00:00Z","timestamp":1565308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-019-6010-9","type":"journal-article","created":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T11:02:36Z","timestamp":1565348556000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5405-2215","authenticated-orcid":false,"given":"Derek","family":"Weycker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Doroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahuva","family":"Hanau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Bowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Belani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Chandler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Lonshteyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bensink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary H.","family":"Lyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,9]]},"reference":[{"issue":"7485","key":"6010_CR1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1136\/bmj.38314.622095.8F","volume":"330","author":"G Bonadonna","year":"2005","unstructured":"Bonadonna G, Moliterni A, Zambetti M, Daidone MG, Pilotti S, Gianni L, et al. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ. 2005;330(7485):217.","journal-title":"BMJ."},{"issue":"4","key":"6010_CR2","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00277-007-0399-y","volume":"87","author":"A Bosly","year":"2008","unstructured":"Bosly A, Bron D, Van Hoof A, De Bock R, Berneman Z, Ferrant A, et al. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol. 2008;87(4):277\u201383.","journal-title":"Ann Hematol"},{"issue":"9","key":"6010_CR3","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1002\/cncr.20983","volume":"103","author":"V Caggiano","year":"2005","unstructured":"Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005;103(9):1916\u201324.","journal-title":"Cancer"},{"issue":"10","key":"6010_CR4","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/cncr.21847","volume":"106","author":"NM Kuderer","year":"2006","unstructured":"Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106(10):2258\u201366.","journal-title":"Cancer"},{"issue":"6","key":"6010_CR5","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1200\/JCO.1990.8.6.963","volume":"8","author":"LW Kwak","year":"1990","unstructured":"Kwak LW, Halpern J, Olshen RA, Horning SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol. 1990;8(6):963\u201377.","journal-title":"J Clin Oncol"},{"issue":"1","key":"6010_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.6004\/jnccn.2009.0009","volume":"7","author":"GH Lyman","year":"2009","unstructured":"Lyman GH. Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Cancer Netw. 2009;7(1):99\u2013108.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"24","key":"6010_CR7","doi-asserted-by":"publisher","first-page":"4524","DOI":"10.1200\/JCO.2003.05.002","volume":"21","author":"GH Lyman","year":"2003","unstructured":"Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003;21(24):4524\u201331.","journal-title":"J Clin Oncol"},{"issue":"3","key":"6010_CR8","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s10549-013-2582-2","volume":"139","author":"GH Lyman","year":"2013","unstructured":"Lyman GH, Dale DC, Tomita D, Whittaker S, Crawford J. A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting. Breast Cancer Res Treat. 2013;139(3):863\u201372.","journal-title":"Breast Cancer Res Treat"},{"issue":"23","key":"6010_CR9","doi-asserted-by":"publisher","first-page":"5555","DOI":"10.1002\/cncr.25332","volume":"116","author":"GH Lyman","year":"2010","unstructured":"Lyman GH, Michels SL, Reynolds MW, Barron R, Tomic KS, Yu J. Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer. 2010;116(23):5555\u201363.","journal-title":"Cancer."},{"issue":"3","key":"6010_CR10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s10549-006-9254-4","volume":"100","author":"M Shayne","year":"2006","unstructured":"Shayne M, Crawford J, Dale DC, Culakova E, Lyman GH, Group ANCS. Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat. 2006;100(3):255\u201362.","journal-title":"Breast Cancer Res Treat"},{"issue":"19","key":"6010_CR11","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","volume":"24","author":"TJ Smith","year":"2006","unstructured":"Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187\u2013205.","journal-title":"J Clin Oncol"},{"issue":"1","key":"6010_CR12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1185\/03007995.2010.536527","volume":"27","author":"H Tan","year":"2011","unstructured":"Tan H, Tomic K, Hurley D, Daniel G, Barron R, Malin J. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study. Curr Med Res Opin. 2011;27(1):79\u201386 Epub 2010\/11\/26.","journal-title":"Curr Med Res Opin"},{"issue":"suppl_5","key":"6010_CR13","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","volume":"27","author":"J Klastersky","year":"2016","unstructured":"Klastersky J, De Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, et al. Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol. 2016;27(suppl_5):v111\u20138.","journal-title":"Ann Oncol"},{"issue":"1","key":"6010_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8\u201332.","journal-title":"Eur J Cancer"},{"issue":"3","key":"6010_CR15","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/COC.0b013e31820dc075","volume":"35","author":"D Weycker","year":"2012","unstructured":"Weycker D, Malin J, Barron R, Edelsberg J, Kartashov A, Oster G. Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy. Am J Clin Oncol. 2012;35(3):267\u201374 Epub 2011\/03\/08.","journal-title":"Am J Clin Oncol"},{"issue":"5","key":"6010_CR16","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1007\/s00520-015-3036-7","volume":"24","author":"D Weycker","year":"2016","unstructured":"Weycker D, Li X, Figueredo J, Barron R, Tzivelekis S, Hagiwara M. Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter? Support Care Cancer. 2016;24(5):2309\u201316 Epub 2015\/11\/27.","journal-title":"Support Care Cancer"},{"issue":"6","key":"6010_CR17","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1007\/s00520-015-3039-4","volume":"24","author":"D Weycker","year":"2016","unstructured":"Weycker D, Li X, Barron R, Li Y, Reiner M, Kartashov A, et al. Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice. Support Care Cancer. 2016;24(6):2481\u201390 Epub 2015\/12\/17.","journal-title":"Support Care Cancer"},{"issue":"12","key":"6010_CR18","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/jnci\/djr152","volume":"103","author":"AL Potosky","year":"2011","unstructured":"Potosky AL, Malin JL, Kim B, Chrischilles EA, Makgoeng SB, Howlader N, et al. Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes. J Natl Cancer Inst. 2011;103(12):979\u201382 Epub 2011\/06\/15.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"6010_CR19","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.clinthera.2009.05.019","volume":"31","author":"D Weycker","year":"2009","unstructured":"Weycker D, Malin J, Kim J, Barron R, Edelsberg J, Kartashov A, et al. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study. Clin Ther. 2009;31(5):1069\u201381 Epub 2009\/06\/23.","journal-title":"Clin Ther"},{"issue":"4","key":"6010_CR20","doi-asserted-by":"crossref","first-page":"337","DOI":"10.18553\/jmcp.2007.13.4.337","volume":"13","author":"VA Morrison","year":"2007","unstructured":"Morrison VA, Wong M, Hershman D, Campos LT, Ding B, Malin J. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices. J Manag Care Pharm. 2007;13(4):337\u201348 Epub 2007\/05\/18.","journal-title":"J Manag Care Pharm"},{"issue":"3","key":"6010_CR21","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1345\/aph.1G516","volume":"40","author":"D Weycker","year":"2006","unstructured":"Weycker D, Hackett J, Edelsberg JS, Oster G, Glass AG. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother. 2006;40(3):402\u20137 Epub 2006\/02\/24.","journal-title":"Ann Pharmacother"},{"issue":"2 Suppl","key":"6010_CR22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.18553\/jmcp.2003.9.s2.15","volume":"9","author":"SD Scott","year":"2003","unstructured":"Scott SD, Chrischilles EA, Link BK, Delgado DJ, Fridman M, Stolshek BS. Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy. J Manag Care Pharm. 2003;9(2 Suppl):15\u201321 Epub 2003\/11\/14.","journal-title":"J Manag Care Pharm"},{"issue":"12","key":"6010_CR23","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1080\/03007995.2017.1386858","volume":"33","author":"D Weycker","year":"2017","unstructured":"Weycker D, Bensink M, Lonshteyn A, Doroff R, Chandler D. Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015. Curr Med Res Opin. 2017;33(12):2107\u201313 Epub 2017\/09\/30.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"6010_CR24","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00520-016-3421-x","volume":"25","author":"D Weycker","year":"2017","unstructured":"Weycker D, Li X, Tzivelekis S, Atwood M, Garcia J, Li Y, et al. Burden of chemotherapy-induced febrile neutropenia hospitalizations in US clinical practice, by use and patterns of prophylaxis with colony-stimulating factor. Support Care Cancer. 2017;25(2):439\u201347 Epub 2016\/10\/14.","journal-title":"Support Care Cancer"},{"issue":"14","key":"6010_CR25","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1200\/JCO.2012.42.8375","volume":"30","author":"LE Schnipper","year":"2012","unstructured":"Schnipper LE, Smith TJ, Raghavan D, Blayney DW, Ganz PA, Mulvey TM, et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol. 2012;30(14):1715\u201324 Epub 2012\/04\/12.","journal-title":"J Clin Oncol"},{"issue":"4","key":"6010_CR26","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1200\/JOP.2012.000662","volume":"9","author":"GE Waters","year":"2013","unstructured":"Waters GE, Corrigan P, Gatesman M, Smith TJ. Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic. J Oncol Pract. 2013;9(4):203\u20136 Epub 2013\/08\/15.","journal-title":"J Oncol Pract"},{"issue":"12","key":"6010_CR27","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1093\/jnci\/djr195","volume":"103","author":"NM Kuderer","year":"2011","unstructured":"Kuderer NM, Lyman GH. Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy. J Natl Cancer Inst. 2011;103(12):910\u20133 Epub 2011\/06\/15.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"6010_CR28","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1080\/03007995.2018.1558851","volume":"35","author":"D Weycker","year":"2019","unstructured":"Weycker D, Bensink M, Lonshteyn A, Doroff R, Chandler D. Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010 to 2016: a longitudinal assessment. Curr Med Res Opin. 2019;35(6):1073\u201380.","journal-title":"Curr Med Res Opin"},{"key":"6010_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1471-2407-13-11","volume":"13","author":"A Naeim","year":"2013","unstructured":"Naeim A, Henk HJ, Becker L, et al. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF). BMC Cancer. 2013;13:11.","journal-title":"BMC Cancer"},{"issue":"3","key":"6010_CR30","first-page":"715","volume":"10","author":"S Siena","year":"2003","unstructured":"Siena S, Piccart MJ, Holmes FA, et al. A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer. Oncol Rep. 2003;10(3):715\u201324.","journal-title":"Oncol Rep"},{"issue":"9","key":"6010_CR31","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1185\/030079907X219599","volume":"23","author":"L Pinto","year":"2007","unstructured":"Pinto L, Liu Z, Doan Q, et al. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2007;23(9):2283\u201395.","journal-title":"Curr Med Res Opin"},{"key":"6010_CR32","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/1471-2407-11-404","volume":"11","author":"KL Cooper","year":"2011","unstructured":"Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer. 2011;11:404.","journal-title":"BMC Cancer"},{"issue":"11","key":"6010_CR33","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1007\/s00520-015-2686-9","volume":"23","author":"L Wang","year":"2015","unstructured":"Wang L, Baser O, Kutikova L, Page JH, Barron R. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer. 2015;23(11):3131\u201340.","journal-title":"Support Care Cancer"},{"issue":"12","key":"6010_CR34","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1517\/14712598.2015.1101063","volume":"15","author":"M Lambertini","year":"2015","unstructured":"Lambertini M, Ferreira AR, Del Mastro L, Danesi R, Pronzato P. Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors. Expert Opin Biol Ther. 2015;15(12):1799\u2013817.","journal-title":"Expert Opin Biol Ther"},{"issue":"12","key":"6010_CR35","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1080\/03007995.2017.1386638","volume":"33","author":"D Weycker","year":"2017","unstructured":"Weycker D, Bensink M, Wu H, Doroff R, Chandler D. Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis based on real-world data from 2010 to 2015. Curr Med Res Opin. 2017;33(12):2115\u201320.","journal-title":"Curr Med Res Opin"},{"key":"6010_CR36","unstructured":"US Department of Health and Human Services (2018) Code of Federal Regulations: Title 45, public welfare; Part 46, protection of human subjects. http:\/\/www.hhs.gov\/ohrp\/humansubjects\/guidance\/45cfr46.html . Accessed 4 July 2019."},{"key":"6010_CR37","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/1472-6963-13-60","volume":"13","author":"D Weycker","year":"2013","unstructured":"Weycker D, Sofrygin O, Seefeld K, Deeter RG, Legg J, Edelsberg J. Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases. BMC Health Serv Res. 2013;13:60.","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"6010_CR38","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/cam4.200","volume":"3","author":"E Culakova","year":"2014","unstructured":"Culakova E, Thota R, Poniewierski MS, Kuderer NM, Wogu AF, Dale DC, et al. Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study. Cancer med. 2014;3(2):434\u201344 Epub 2014\/04\/08.","journal-title":"Cancer med"},{"issue":"21","key":"6010_CR39","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","volume":"25","author":"NM Kuderer","year":"2007","unstructured":"Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25(21):3158\u201367 Epub 2007\/07\/20.","journal-title":"J Clin Oncol"},{"issue":"34","key":"6010_CR40","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1200\/JCO.2012.44.6229","volume":"31","author":"MJ Aarts","year":"2013","unstructured":"Aarts MJ, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ, et al. Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia. J Clin Oncol. 2013;31(34):4290\u20136 Epub 2013\/05\/01.","journal-title":"J Clin Oncol"},{"issue":"3","key":"6010_CR41","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00520-012-1589-2","volume":"21","author":"S Lee","year":"2013","unstructured":"Lee S, Knox A, Zeng IS, Coomarasamy C, Blacklock H, Issa S. Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cost-benefit and quality of life analysis. Support Care Cancer. 2013;21(3):841\u20136 Epub 2012\/09\/14.","journal-title":"Support Care Cancer"},{"issue":"8","key":"6010_CR42","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1007\/s00520-014-2184-5","volume":"22","author":"WJ Langeberg","year":"2014","unstructured":"Langeberg WJ, Siozon CC, Page JH, Morrow PK, Chia VM. Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin's lymphoma. Support Care Cancer. 2014;22(8):2167\u201375 Epub 2014\/03\/22.","journal-title":"Support Care Cancer"},{"issue":"11","key":"6010_CR43","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1007\/s00520-015-2686-9","volume":"23","author":"L Wang","year":"2015","unstructured":"Wang L, Baser O, Kutikova L, Page JH, Barron R. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer. 2015;23(11):3131\u201340 Epub 2015\/03\/31.","journal-title":"Support Care Cancer"},{"issue":"3","key":"6010_CR44","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.3747\/co.20.1306","volume":"20","author":"AK Altwairgi","year":"2013","unstructured":"Altwairgi AK, Hopman WM, Mates M. Real-world impact of granulocyte-colony stimulating factor on febrile neutropenia. Curr Oncol. 2013;20(3):e171\u20139.","journal-title":"Curr Oncol"},{"issue":"12","key":"6010_CR45","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1002\/phar.1150","volume":"32","author":"AM Bradley","year":"2012","unstructured":"Bradley AM, Deal AM, Buie LW, van Deventer H. Neutropenia-associated outcomes in adults with acute myeloid leukemia receiving cytarabine consolidation chemotherapy with or without granulocyte colony-stimulating factor. Pharmacother. 2012;32(12):1070\u20137.","journal-title":"Pharmacother"},{"issue":"3","key":"6010_CR46","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3111\/13696990903238603","volume":"12","author":"D Hershman","year":"2009","unstructured":"Hershman D, Hurley D, Wong M, Morrison VA, Malin JL. Impact of primary prophylaxis on febrile neutropenia within community practices in the US. J Med Econ. 2009;12(3):203\u201310.","journal-title":"J Med Econ"},{"key":"6010_CR47","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Myeloid Growth Factors. Version 1. 2018. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/growthfactors.pdf . cited 25 July 2018."},{"issue":"5","key":"6010_CR48","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3111\/13696998.2016.1140052","volume":"19","author":"JM Stephens","year":"2016","unstructured":"Stephens JM, Li X, Reiner M, Tzivelekis S. Annual patient and caregiver burden of oncology clinic visits for granulocyte-colony stimulating factor therapy in the US. J Med Econ. 2016;19(5):537\u201347 Epub 2016\/01\/09.","journal-title":"J Med Econ"},{"issue":"8","key":"6010_CR49","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1080\/03007995.2017.1358158","volume":"34","author":"JM Stephens","year":"2018","unstructured":"Stephens JM, Bensink M, Bowers C, Hollenbeak CS. Travel burden associated with granulocyte colony-stimulating factor administration in a Medicare aged population: a geospatial analysis. Curr Med Res Opin. 2018;34(8):1351\u201360 Epub 2017\/07\/20.","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"6010_CR50","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1093\/annonc\/mdt226","volume":"24","author":"GH Lyman","year":"2013","unstructured":"Lyman GH, Dale DC, Culakova E, Poniewierski MS, Wolff DA, Kuderer NM, et al. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol. 2013;24(10):2475\u201384 Epub 2013\/06\/22.","journal-title":"Ann Oncol"},{"issue":"8","key":"6010_CR51","doi-asserted-by":"publisher","first-page":"979","DOI":"10.6004\/jnccn.2015.0118","volume":"13","author":"D Weycker","year":"2015","unstructured":"Weycker D, Li X, Barron R, Wu H, Morrow PK, Xu H, et al. Importance of risk factors for febrile neutropenia among patients receiving chemotherapy regimens not classified as high-risk in guidelines for myeloid growth factor use. J Natl Compr Cancer Netw. 2015;13(8):979\u201386.","journal-title":"J Natl Compr Cancer Netw"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6010-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-6010-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6010-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,16]],"date-time":"2021-01-16T11:10:31Z","timestamp":1610795431000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-6010-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,9]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["6010"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-6010-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,9]]},"assertion":[{"value":"18 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The data extracts were de-identified prior to their release to study investigators, and thus their use for health services research is compliant with the HIPAA Privacy Rule and federal guidance on Public Welfare and the Protection of Human Subjects and is exempt from IRB review.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DW, RD, AH, and AL are employed by Policy Analysis Inc. (PAI). CB, RB, DC, and MB are employed by, and own stock in, Amgen Inc. GHL is the principal investigator on a research grant to Fred Hutchinson Cancer Research Center from Amgen Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"792"}}